SEC 13F Intelligence

Managers / Q1 2025 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$115M
Q1 2025
Positions
68
Filings on Record
39
2019–present window
Filed
May 15, 2025
original filing

Summary

Birchview Capital, LP reported $115M in U.S.-listed holdings across 68 positions for Q1 2025.

The portfolio is heavily concentrated: BMY alone accounts for 36.3% of reported value.

Compared with Q4 2024, the fund opened 4 new positions and exited 4.

Portfolio Metrics

Turnover
+9.8%
vs prior filed quarter
Top-10 Concentration
+66.1%
share of reported value
Largest Position
+36.3%
Bristol Myers Squibb
New / Exited
4 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 89.3%Other: 10.5%ETP: 0.1%
  • Common Stock · 89.3% · $103M
  • Other · 10.5% · $12M
  • ETP · 0.1% · $144,400

Quarter-over-Quarter Changes full breakdown →

vs Q4 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
KIDSORTHOPEDIATRICS CORPNEW+20.0K20.0K+$492,600$492,600
SLDBSOLID BIOSCIENCES INCNEW+128.8K128.8K+$476,442$476,442
APGEAPOGEE THERAPEUTICS INCNEW+8.0K8.0K+$298,880$298,880
CMPXCOMPASS THERAPEUTICS INCNEW+24.0K24.0K+$45,600$45,600
UNIQURE NVADDED+68.7K88.7K+$586,988$940,188
XENEXENON PHARMACEUTICALS INCADDED+11.0K21.0K+$312,550$704,550
SRPTSAREPTA THERAPEUTICS INCSOLD OUT−3.5K0−$425,565$0
BIOHAVEN PHARMACEUTICAL HOLDING CO LTDSOLD OUT−7.4K0−$275,083$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2025

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM36.29%$42M685.2K
2HTDCORCEPT THERAPEUTICS INChistory →COM6.55%$8M66.0K
3ACADACADIA PHARMACEUTICALS INChistory →COM3.80%$4M263.4K
4PROTHENA CORP PLCSHS3.58%$4M333.0K
5BIODESIX INCCOM3.11%$4M5.74M
6NBIXNEUROCRINE BIOSCIENCES INChistory →COM2.90%$3M30.2K
7ELUTELUTIA INChistory →COM2.61%$3M1.19M
8AXGNAXOGEN INChistory →COM2.59%$3M161.0K
9PHRPHREESIA INChistory →COM2.55%$3M114.7K
10TVTXTRAVERE THERAPEUTICS INChistory →COM2.15%$2M138.0K
11QDEL*QUIDELORTHO CORPhistory →COM2.05%$2M67.6K
12PTGXPROTAGONIST THERAPEUTICS INChistory →COM2.02%$2M48.0K
13UTHUNITED THERAPEUTICS CORPhistory →COM2.01%$2M7.5K
14DCGODOCGO INChistory →COM1.98%$2M864.1K
15OVVOVINTIV INChistory →COM1.94%$2M52.2K
16HROWHARROW HEALTH INChistory →COM1.68%$2M72.9K
17MASI*MASIMO CORPhistory →COM1.63%$2M11.3K
18EQTEQT CORPORATIONhistory →COM1.61%$2M34.6K
19CSTLCASTLE BIOSCIENCES INChistory →COM1.54%$2M88.4K
20ALKERMES PLCSHS1.43%$2M50.0K
21STOKSTOKE THERAPEUTICS INChistory →COM1.21%$1M210.0K
22TMCITREACE MEDICAL CONCEPTS INChistory →COM1.20%$1M164.9K
23FHTXFOGHORN THERAPEUTICS INCCOM0.99%$1M310.9K
24UNIQURE NVSHS0.82%$940,18888.7K
254XC1KALVISTA PHARMACEUTICALS INCCOM0.67%$773,19967.0K
26XENEXENON PHARMACEUTICALS INCCOM0.61%$704,55021.0K
27AXSMAXSOME THERAPEUTICS INCCOM0.61%$699,7806.0K
28KINIKSA PHARMACEUTICALS LTDCOM0.58%$666,44430.0K
29HALOHALOZYME THERAPEUTICS INCCOM0.55%$638,10010.0K
30RAREULTRAGENYX PHARMACEUTICAL INCCOM0.50%$579,36016.0K
31NOVOCURE LTDORD SHS0.48%$552,42031.0K
32SRRKSCHOLAR ROCK HOLDING CORPCOM0.45%$514,40016.0K
33KIDSORTHOPEDIATRICS CORPCOM0.43%$492,60020.0K
34SLDBSOLID BIOSCIENCES INCCOM NEW0.41%$476,442128.8K
35INBXINHIBRX BIOSCIENCES INCCOM0.39%$449,21932.1K
36TXG10X GENOMICS INCCL A COM0.38%$436,50050.0K
37CYTKCYTOKINETICS INCCOM0.35%$401,90010.0K
38SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.32%$365,3968.3K
39LUNGPULMONX CORPCOM0.30%$343,23051.0K
40CADLCANDEL THERAPEUTICS INCCOM0.29%$339,00060.0K
41ATECALPHATEC HOLDINGS INCCOM0.29%$334,62033.0K
42WAVE LIFE SCIENCES LTDSHS0.28%$325,62440.3K
43MLTXMOONLAKE IMMUNOTHERAPEUTICSCLASS A ORD0.27%$312,5608.0K
44APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.27%$306,18014.0K
45BCRXBIOCRYST PHARMACEUTICALS INCCOM0.26%$300,00040.0K
46APGEAPOGEE THERAPEUTICS INCCOM0.26%$298,8808.0K
47XNCRXENCOR INCCOM0.24%$276,64026.0K
48OMGBPOUTSET MEDICAL INCCOM0.24%$271,89924.6K
492655787DBLUEPRINT MEDICINES CORPCOM0.21%$238,9772.7K
50AM6AMICUS THERAPEUTICS INCCOM0.20%$228,48028.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.